30 March 2023 
EMA/141466/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Wegovy 
semaglutide 
On 30 March 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Wegovy. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S. 
The CHMP adopted an extension to the existing indication as follows:2 
Adults 
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for 
weight management, including weight loss and weight maintenance, in adults with an initial 
Body Mass Index (BMI) of  
•  ≥30 kg/m2 (obesity), or  
•  ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related 
comorbidity e.g. dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, 
dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. 
Adolescents (≥12 years) 
Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical 
activity for weight management in adolescents ages 12 years and above with  
•  obesity* and 
•  body weight above 60 kg 
Treatment with Wegovy should be discontinued and re-evaluated if adolescent 
patients have not reduced their BMI by at least 5% after 12 weeks on the 2.4 mg or 
maximum tolerated dose. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
*Obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth 
charts (CDC.gov) (see Table 1). 
Table 1 BMI cut-off points for obesity (≥95th percentile) by sex and age for paediatric 
patients aged 12 and older (CDC criteria) 
Age (years) 
12 
12.5 
13 
13.5 
14 
14.5 
15 
15.5 
16 
16.5 
17 
17.5 
BMI (kg/m2) at 95th Percentile 
Males 
24.2 
24.7 
25.1 
25.6 
26.0 
26.4 
26.8 
27.2 
27.5 
27.9 
28.2 
28.6 
Females 
25.2 
25.7 
26.3 
26.8 
27.2 
27.7 
28.1 
28.5 
28.9 
29.3 
29.6 
30.0 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
Wegovy  
EMA/141466/2023 
Page 2/2 
 
 
 
 
 
